{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:16:37Z","timestamp":1773256597487,"version":"3.50.1"},"reference-count":31,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.2967\/jnumed.122.263856","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T21:30:14Z","timestamp":1654810214000},"page":"40-46","source":"Crossref","is-referenced-by-count":13,"title":["Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with<sup>177<\/sup>Lu-DOTATATE in Neuroendocrine Tumor Patients"],"prefix":"10.2967","volume":"64","author":[{"given":"No\u00e9mie S.","family":"Minczeles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter W.","family":"de Herder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik A.","family":"Verburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa","family":"Brabander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1602","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"2023031310502069000_64.1.40.1","doi-asserted-by":"crossref","unstructured":"Hofland J Kaltsas G de Herder WW . Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev. 2020;41:371\u2013403.","DOI":"10.1210\/endrev\/bnz004"},{"key":"2023031310502069000_64.1.40.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.304"},{"key":"2023031310502069000_64.1.40.3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2743"},{"key":"2023031310502069000_64.1.40.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2023031310502069000_64.1.40.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1902-1"},{"key":"2023031310502069000_64.1.40.6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/RLU.0000000000001629","article-title":"Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with somatostatin receptor expressing neuroendocrine tumors: six years\u2019 assessment","volume":"42","author":"Hamiditabar","year":"2017","journal-title":"Clin Nucl Med."},{"key":"2023031310502069000_64.1.40.7","doi-asserted-by":"crossref","first-page":"e212274","DOI":"10.1001\/jamanetworkopen.2021.2274","article-title":"Laboratory, clinical, and survival outcomes associated with peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors","volume":"4","author":"Kipnis","year":"2021","journal-title":"JAMA Netw Open."},{"key":"2023031310502069000_64.1.40.8","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/imj.14336","article-title":"Safety and outcomes of 177Lu-DOTATATE for neuroendocrine tumours: experience in New South Wales, Australia","volume":"49","author":"Lin","year":"2019","journal-title":"Intern Med J."},{"key":"2023031310502069000_64.1.40.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3041-6"},{"key":"2023031310502069000_64.1.40.10","doi-asserted-by":"publisher","DOI":"10.1111\/his.13975"},{"key":"2023031310502069000_64.1.40.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2023031310502069000_64.1.40.12","doi-asserted-by":"publisher","DOI":"10.1136\/fmch-2019-000262"},{"key":"2023031310502069000_64.1.40.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.107524"},{"key":"2023031310502069000_64.1.40.14","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"2023031310502069000_64.1.40.15","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3748\/wjg.v26.i13.1513","article-title":"Evaluation of 177Lu-DOTATATE treatment in patients with metastatic neuroendocrine tumors and prognostic factors","volume":"26","author":"Abou Jokh Casas","year":"2020","journal-title":"World J Gastroenterol."},{"key":"2023031310502069000_64.1.40.16","doi-asserted-by":"publisher","DOI":"10.1159\/000197899"},{"key":"2023031310502069000_64.1.40.17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00432-021-03672-w","article-title":"Survival predictors of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)","volume":"148","author":"Swiha","year":"2022","journal-title":"J Cancer Res Clin Oncol."},{"key":"2023031310502069000_64.1.40.18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000442983","article-title":"Malnutrition predicts clinical outcome in patients with neuroendocrine neoplasia","volume":"104","author":"Maasberg","year":"2017","journal-title":"Neuroendocrinology."},{"key":"2023031310502069000_64.1.40.19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","article-title":"Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023031310502069000_64.1.40.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.119347"},{"key":"2023031310502069000_64.1.40.21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1159\/000504001","article-title":"177Lu-DOTATATE peptide receptor radionuclide therapy: dose response in small intestinal neuroendocrine tumors","volume":"110","author":"Jahn","year":"2020","journal-title":"Neuroendocrinology."},{"key":"2023031310502069000_64.1.40.22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00259-016-3533-z","article-title":"Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-DOTATATE","volume":"44","author":"Sansovini","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023031310502069000_64.1.40.23","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00259-014-2735-5","article-title":"177Lu-DOTA-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study","volume":"41","author":"Paganelli","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023031310502069000_64.1.40.24","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial","volume":"46","author":"Del Prete","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023031310502069000_64.1.40.25","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","article-title":"Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity","volume":"45","author":"Garske-Rom\u00e1n","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023031310502069000_64.1.40.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510"},{"key":"2023031310502069000_64.1.40.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316158"},{"key":"2023031310502069000_64.1.40.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00817-X"},{"key":"2023031310502069000_64.1.40.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290"},{"key":"2023031310502069000_64.1.40.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003825"},{"key":"2023031310502069000_64.1.40.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.165803"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.263856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T17:52:25Z","timestamp":1678729945000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.263856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,4]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.2967\/jnumed.122.263856"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.263856","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]}}}